DVAX - NASDAQ
Dynavax Technologies Corporation
$15.50
+0.0000%Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
At a Glance
Live Snapshotdvax
Total Equity
Last Annual Value
596.80M
3-Year CAGR
39%
5-Year CAGR
135%
10-Year CAGR
20%
Dynavax Technologies Corporation Competitors Analysis of Total Equity
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Dynavax Technologies Corporation NASDAQ:DVAX | 596.80M | -1.4% | 21.8% | 20.9% | |
 Enliven Therapeutics, Inc. NASDAQ:ELVN | 459.60M | 23.2% | 33.9% | N/A | |
 STAAR Surgical Company NASDAQ:STAA | 344.18M | -3.7% | 5.9% | 24.7% | |
 Pacira BioSciences, Inc. NASDAQ:PCRX | 693.11M | -7.3% | -1.0% | 12.2% | |
 Amphastar Pharmaceuticals, Inc. NASDAQ:AMPH | 788.80M | 7.2% | 12.1% | 9.1% | |
 Beta Bionics, Inc. NASDAQ:BBNX | 287.61M | 69.9% | N/A | N/A | |
 Pulse Biosciences, Inc. NASDAQ:PLSE | 80.66M | 22.1% | 17.7% | 12.3% | |
 Collegium Pharmaceutical, Inc. NASDAQ:COLL | 301.68M | 15.6% | 8.3% | 8.4% | |
 Harrow Health, Inc. NASDAQ:HROW | 52.09M | -9.4% | 36.7% | 23.3% |
Dynavax Technologies Corporation Fair Value Envelope
Related Guides
Continue your DVAX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.